Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 285

1.

Adjuvant chemotherapy improves overall survival in patients with localized upper tract urothelial carcinoma harboring pathologic vascular invasion: a propensity score-matched analysis of multi-institutional cohort.

Matsunaga T, Komura K, Hashimoto T, Muraoka R, Satake N, Tsutsumi T, Tsujino T, Yoshikawa Y, Takai T, Minami K, Taniguchi K, Tanaka T, Uehara H, Hirano H, Nomi H, Ibuki N, Takahara K, Inamoto T, Ohno Y, Azuma H.

World J Urol. 2020 Feb 17. doi: 10.1007/s00345-020-03118-x. [Epub ahead of print]

PMID:
32065276
2.

Down-Grading of Ipsilateral Hydronephrosis by Neoadjuvant Chemotherapy Correlates with Favorable Oncological Outcomes in Patients Undergoing Radical Nephroureterectomy for Ureteral Carcinoma.

Miyake M, Marugami N, Fujiwara Y, Komura K, Inamoto T, Azuma H, Matsumoto H, Matsuyama H, Fujimoto K.

Diagnostics (Basel). 2019 Dec 23;10(1). pii: E10. doi: 10.3390/diagnostics10010010.

3.

Editorial Comment to Prognostic significance of common preoperative laboratory variables in penile squamous cell carcinoma.

Inamoto T, Azuma H.

Int J Urol. 2020 Jan;27(1):82. doi: 10.1111/iju.14173. Epub 2019 Dec 18. No abstract available.

PMID:
31852022
4.

Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer.

Uchimoto T, Komura K, Fujiwara Y, Saito K, Tanda N, Matsunaga T, Ichihashi A, Tsutsumi T, Tsujino T, Yoshikawa Y, Nishimoto Y, Takai T, Minami K, Taniguchi K, Tanaka T, Uehara H, Hirano H, Nomi H, Ibuki N, Takahara K, Inamoto T, Azuma H.

Med Oncol. 2019 Nov 21;37(1):9. doi: 10.1007/s12032-019-1332-7.

PMID:
31754918
5.

Influence of the Body Mass Index and its Effect on Tumor Characteristics and Survival among a Population with Access to Surgical Management of Upper Tract Urothelial Carcinoma.

Inamoto T, Sassa N, Hattori R, Ibuki N, Komura K, Minami K, Takai T, Uchimoto T, Saito K, Tanda N, Tsujino T, Sano T, Kato M, Tsuzuki T, Gotoh M, Azuma H.

Curr Urol. 2019 Jul;12(4):201-209. doi: 10.1159/000499305. Epub 2019 Jul 20.

6.

Editorial Comment to C-reactive protein can be used to predict the therapeutic effects of nivolumab in patients with metastatic renal cell carcinoma.

Inamoto T, Azuma H.

Int J Urol. 2019 Nov;26(11):1078. doi: 10.1111/iju.14114. Epub 2019 Sep 22. No abstract available.

PMID:
31544266
7.

Comparison of Radiographic Progression-Free Survival and PSA Response on Sequential Treatment Using Abiraterone and Enzalutamide for Newly Diagnosed Castration-Resistant Prostate Cancer: A Propensity Score Matched Analysis from Multicenter Cohort.

Komura K, Fujiwara Y, Uchimoto T, Saito K, Tanda N, Matsunaga T, Ichihashi A, Tsutsumi T, Tsujino T, Yoshikawa Y, Nishimoto Y, Takai T, Minami K, Taniguchi K, Tanaka T, Uehara H, Hirano H, Nomi H, Ibuki N, Takahara K, Inamoto T, Azuma H.

J Clin Med. 2019 Aug 19;8(8). pii: E1251. doi: 10.3390/jcm8081251.

8.

Effectiveness and safety of surgical glove compression therapy as a prophylactic method against nanoparticle albumin-bound-paclitaxel-induced peripheral neuropathy.

Tsuyuki S, Yamagami K, Yoshibayashi H, Sugie T, Mizuno Y, Tanaka S, Kato H, Okuno T, Ogura N, Yamashiro H, Takuwa H, Kikawa Y, Hashimoto T, Kato T, Takahara S, Katayama T, Yamauchi A, Inamoto T.

Breast. 2019 Oct;47:22-27. doi: 10.1016/j.breast.2019.06.008. Epub 2019 Jul 3.

PMID:
31302389
9.

The CANLPH Score, an Integrative Model of Systemic Inflammation and Nutrition Status (SINS), Predicts Clinical Outcomes After Surgery in Renal Cell Carcinoma: Data From a Multicenter Cohort in Japan.

Komura K, Hashimoto T, Tsujino T, Muraoka R, Tsutsumi T, Satake N, Matsunaga T, Yoshikawa Y, Takai T, Minami K, Taniguchi K, Uehara H, Tanaka T, Hirano H, Nomi H, Ibuki N, Takahara K, Inamoto T, Ohno Y, Azuma H.

Ann Surg Oncol. 2019 Sep;26(9):2994-3004. doi: 10.1245/s10434-019-07530-5. Epub 2019 Jun 25.

PMID:
31240592
10.

MicroRNA-143/Musashi-2/KRAS cascade contributes positively to carcinogenesis in human bladder cancer.

Tsujino T, Sugito N, Taniguchi K, Honda R, Komura K, Yoshikawa Y, Takai T, Minami K, Kuranaga Y, Shinohara H, Tokumaru Y, Heishima K, Inamoto T, Azuma H, Akao Y.

Cancer Sci. 2019 Jul;110(7):2189-2199. doi: 10.1111/cas.14035. Epub 2019 May 27.

11.

C-reactive protein-albumin ratio as a prognostic factor in renal cell carcinoma - A data from multi-institutional study in Japan.

Tsujino T, Komura K, Hashimoto T, Muraoka R, Satake N, Matsunaga T, Tsutsumi T, Yoshikawa Y, Takai T, Minami K, Uehara H, Hirano H, Nomi H, Ibuki N, Takahara K, Inamoto T, Ohno Y, Azuma H.

Urol Oncol. 2019 Nov;37(11):812.e1-812.e8. doi: 10.1016/j.urolonc.2019.04.002. Epub 2019 Apr 30.

PMID:
31053528
12.

Synthetic miR-143 Exhibited an Anti-Cancer Effect via the Downregulation of K-RAS Networks of Renal Cell Cancer Cells In Vitro and In Vivo.

Takai T, Tsujino T, Yoshikawa Y, Inamoto T, Sugito N, Kuranaga Y, Heishima K, Soga T, Hayashi K, Miyata K, Kataoka K, Azuma H, Akao Y.

Mol Ther. 2019 May 8;27(5):1017-1027. doi: 10.1016/j.ymthe.2019.03.004. Epub 2019 Mar 13.

13.

Anti-cancer Effects of a Chemically Modified miR-143 on Bladder Cancer by Either Systemic or Intravesical Treatment.

Yoshikawa Y, Taniguchi K, Tsujino T, Heishima K, Inamoto T, Takai T, Minami K, Azuma H, Miyata K, Hayashi K, Kataoka K, Akao Y.

Mol Ther Methods Clin Dev. 2019 Feb 20;13:290-302. doi: 10.1016/j.omtm.2019.02.005. eCollection 2019 Jun 14.

14.

Effect of Systematic Conversion to Generic Mycophenolate Mofetil (MMF) in Kidney Transplantation: A Single-Center Clinical Experience from Japan.

Hirano H, Matsunaga T, Maenosono R, Taniguchi S, Uehara H, Nomi H, Kano Y, Fujiwara Y, Ichihashi A, Kobayashi D, Tsutsumi T, Komura K, Ibuki N, Inamoto T, Matsumura H, Ashida A, Azuma H.

Transplant Proc. 2018 Dec;50(10):3255-3257. doi: 10.1016/j.transproceed.2018.04.064. Epub 2018 May 4.

PMID:
30577194
15.

Risk stratification by means of biological age-related factors better predicts cancer-specific survival than chronological age in patients with upper tract urothelial carcinoma: a multi-institutional database study.

Inamoto T, Matsuyama H, Ibuki N, Komura K, Fujimoto K, Shiina H, Sakano S, Nagao K, Miyake M, Yasumoto H, Azuma H; Nishinihon Uro-Oncology Collaborative Group.

Ther Adv Urol. 2018 Nov 11;10(12):403-410. doi: 10.1177/1756287218811050. eCollection 2018 Dec.

16.

Tetramodal therapy using balloon-occluded arterial infusion of anticancer agents, the Azuma regimen, for lymph node-involved bladder cancer.

Azuma H, Inamoto T, Takahara K, Ibuki N, Nomi H, Komura K, Uehara H, Minami K, Yamamoto K, Narumi Y.

Int J Oncol. 2019 Jan;54(1):167-176. doi: 10.3892/ijo.2018.4619. Epub 2018 Nov 2.

PMID:
30387836
17.
18.

Safety of Elderly Living Kidney Donors: 2 Cases of Donors Older Than 80 Years: A Case Report.

Hirano H, Maenosono R, Matsunaga T, Uehara H, Nomi H, Ichihashi A, Kobayashi D, Taniguchi S, Tsutsumi T, Tsujino T, Komura K, Ibuki N, Inamoto T, Azuma H.

Transplant Proc. 2018 Oct;50(8):2569-2571. doi: 10.1016/j.transproceed.2018.03.093. Epub 2018 Mar 19.

PMID:
30316400
19.

Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm.

Takada M, Sugimoto M, Masuda N, Iwata H, Kuroi K, Yamashiro H, Ohno S, Ishiguro H, Inamoto T, Toi M.

Breast Cancer Res Treat. 2018 Dec;172(3):611-618. doi: 10.1007/s10549-018-4958-9. Epub 2018 Sep 7.

PMID:
30194511
20.

A Panel of MicroRNA Signature as a Tool for Predicting Survival of Patients with Urothelial Carcinoma of the Bladder.

Inamoto T, Uehara H, Akao Y, Ibuki N, Komura K, Takahara K, Takai T, Uchimoto T, Saito K, Tanda N, Yoshikawa Y, Minami K, Hirano H, Nomi H, Kato R, Hayashi T, Azuma H.

Dis Markers. 2018 Jun 20;2018:5468672. doi: 10.1155/2018/5468672. eCollection 2018.

21.

ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D.

Komura K, Yoshikawa Y, Shimamura T, Chakraborty G, Gerke TA, Hinohara K, Chadalavada K, Jeong SH, Armenia J, Du SY, Mazzu YZ, Taniguchi K, Ibuki N, Meyer CA, Nanjangud GJ, Inamoto T, Lee GM, Mucci LA, Azuma H, Sweeney CJ, Kantoff PW.

J Clin Invest. 2018 Jul 2;128(7):2979-2995. doi: 10.1172/JCI96769. Epub 2018 Jun 4.

22.

Dual Gas Treatment With Hydrogen and Carbon Monoxide Attenuates Oxidative Stress and Protects From Renal Ischemia-Reperfusion Injury.

Nishida T, Hayashi T, Inamoto T, Kato R, Ibuki N, Takahara K, Takai T, Yoshikawa Y, Uchimoto T, Saito K, Tanda N, Kouno J, Minami K, Uehara H, Hirano H, Nomi H, Okada Y, Azuma H.

Transplant Proc. 2018 Jan - Feb;50(1):250-258. doi: 10.1016/j.transproceed.2017.12.014.

PMID:
29407319
23.

[A Case of Retroperitoneal Teratoma Difficult to Distinguish from Adrenal Tumor].

Maenosono R, Saito K, Ibuki N, Takahara K, Inamoto T, Nomi H, Azuma H.

Hinyokika Kiyo. 2017 Dec;63(12):525-528. doi: 10.14989/ActaUrolJap_63_12_525. Review. Japanese.

24.

The systemic inflammation-based Glasgow Prognostic Score as a powerful prognostic factor in patients with upper tract urothelial carcinoma.

Inamoto T, Matsuyama H, Sakano S, Ibuki N, Takahara K, Komura K, Takai T, Tsujino T, Yoshikawa Y, Minami K, Nagao K, Inoue R, Azuma H.

Oncotarget. 2017 Nov 23;8(68):113248-113257. doi: 10.18632/oncotarget.22641. eCollection 2017 Dec 22.

25.

The combination of preoperative platelet count and neutrophil lymphocyte ratio as a prognostic indicator in localized renal cell carcinoma.

Tsujino T, Komura K, Ichihashi A, Tsutsumi T, Matsunaga T, Yoshikawa Y, Maenosono R, Okita K, Takai T, Oide R, Minami K, Uehara H, Taniguchi K, Hirano H, Nomi H, Ibuki N, Takahara K, Inamoto T, Azuma H.

Oncotarget. 2017 Nov 25;8(66):110311-110325. doi: 10.18632/oncotarget.22688. eCollection 2017 Dec 15.

26.

Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.

Miyake M, Tatsumi Y, Matsumoto H, Nagao K, Matsuyama H, Inamoto T, Azuma H, Yasumoto H, Shiina H, Fujimoto K; Nishinihon Uro-Oncology Collaborative Group.

BJU Int. 2018 May;121(5):764-773. doi: 10.1111/bju.14111. Epub 2018 Jan 21.

27.

Current treatment strategies for advanced prostate cancer.

Komura K, Sweeney CJ, Inamoto T, Ibuki N, Azuma H, Kantoff PW.

Int J Urol. 2018 Mar;25(3):220-231. doi: 10.1111/iju.13512. Epub 2017 Dec 20. Review.

28.

Thermoelectric properties of nanocrystalline Sb2Te3 thin films: experimental evaluation and first-principles calculation, addressing effect of crystal grain size.

Morikawa S, Inamoto T, Takashiri M.

Nanotechnology. 2018 Feb 16;29(7):075701. doi: 10.1088/1361-6528/aaa31f.

PMID:
29260732
29.

Adjuvant chemotherapy improves survival of patients with high-risk upper urinary tract urothelial carcinoma: a propensity score-matched analysis.

Fujita K, Taneishi K, Inamoto T, Ishizuya Y, Takada S, Tsujihata M, Tanigawa G, Minato N, Nakazawa S, Takada T, Iwanishi T, Uemura M, Okuno Y, Azuma H, Norio N.

BMC Urol. 2017 Dec 1;17(1):110. doi: 10.1186/s12894-017-0305-4.

30.

Can bladder preservation therapy come to the center stage?

Inamoto T, Ibuki N, Komura K, Juri H, Yamamoto K, Yamamoto K, Fujita K, Nonomura N, Narumi Y, Azuma H.

Int J Urol. 2018 Feb;25(2):134-140. doi: 10.1111/iju.13495. Epub 2017 Nov 23. Review.

31.

Biological Behavior and Long-Term Outcomes of Carcinoma In Situ in Upper Urinary Tract Managed by Radical Nephroureterectomy.

Inamoto T, Matsuyama H, Ibuki N, Komura K, Takahara K, Fujimoto K, Shiina H, Sakano S, Nagao K, Miyake M, Tatsumi Y, Yasumoto H, Azuma H; Nishinihon Uro-Oncology Collaborative Group.

J Urol. 2018 Apr;199(4):933-939. doi: 10.1016/j.juro.2017.10.019. Epub 2017 Oct 14.

PMID:
29037861
32.

Anti-Inflammatory Thioredoxin Family Proteins for Medicare, Healthcare and Aging Care.

Yodoi J, Matsuo Y, Tian H, Masutani H, Inamoto T.

Nutrients. 2017 Sep 29;9(10). pii: E1081. doi: 10.3390/nu9101081. Review.

33.

Spontaneous rupture of the urinary bladder (SRUB): Recovery from cardiopulmonary arrest.

Taniguchi K, Iida R, Ota K, Nitta M, Tsujino T, Komura K, Inamoto T, Azuma H, Uchiyama K, Takasu A.

Am J Emerg Med. 2017 Oct;35(10):1584.e5-1584.e7. doi: 10.1016/j.ajem.2017.07.058. Epub 2017 Jul 18.

PMID:
28751042
34.

Preoperative Measurement of the Modified Glasgow Prognostic Score Predicts Patient Survival in Non-Metastatic Renal Cell Carcinoma Prior to Nephrectomy.

Tsujino T, Komura K, Matsunaga T, Yoshikawa Y, Takai T, Uchimoto T, Saito K, Tanda N, Oide R, Minami K, Uehara H, Jeong SH, Taniguchi K, Hirano H, Nomi H, Ibuki N, Takahara K, Inamoto T, Azuma H.

Ann Surg Oncol. 2017 Sep;24(9):2787-2793. doi: 10.1245/s10434-017-5948-6. Epub 2017 Jun 22.

PMID:
28643013
35.

Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report.

Tsujino T, Takahara K, Matsunaga T, Yoshikawa Y, Takai T, Uchimoto T, Saito K, Tanda N, Hirano H, Nomi H, Ibuki N, Inamoto T, Azuma H.

J Med Case Rep. 2017 Apr 10;11(1):99. doi: 10.1186/s13256-017-1263-x.

36.

MiR-145 negatively regulates Warburg effect by silencing KLF4 and PTBP1 in bladder cancer cells.

Minami K, Taniguchi K, Sugito N, Kuranaga Y, Inamoto T, Takahara K, Takai T, Yoshikawa Y, Kiyama S, Akao Y, Azuma H.

Oncotarget. 2017 May 16;8(20):33064-33077. doi: 10.18632/oncotarget.16524.

37.

A Novel Combination RNAi toward Warburg Effect by Replacement with miR-145 and Silencing of PTBP1 Induces Apoptotic Cell Death in Bladder Cancer Cells.

Takai T, Yoshikawa Y, Inamoto T, Minami K, Taniguchi K, Sugito N, Kuranaga Y, Shinohara H, Kumazaki M, Tsujino T, Takahara K, Ito Y, Akao Y, Azuma H.

Int J Mol Sci. 2017 Jan 17;18(1). pii: E179. doi: 10.3390/ijms18010179.

38.

Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a phase II multicenter study by the Kamigata Breast Cancer Study Group.

Tsuyuki S, Senda N, Kanng Y, Yamaguchi A, Yoshibayashi H, Kikawa Y, Katakami N, Kato H, Hashimoto T, Okuno T, Yamauchi A, Inamoto T.

Breast Cancer Res Treat. 2016 Nov;160(1):61-67. Epub 2016 Sep 12.

PMID:
27620884
39.

Changes in oncological outcomes after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma treated in the last two decades: a retrospective analysis based on a multicenter collaborative study.

Miyake M, Tatsumi Y, Fujimoto K, Nagao K, Sakano S, Matsuyama H, Inamoto T, Azuma H, Yasumoto H, Shiina H; Nishinipon Uro-Oncology Collaborative Group.

Jpn J Clin Oncol. 2016 Dec;46(12):1148-1155. Epub 2016 Aug 30.

PMID:
27576438
40.

microRNA-145 Mediates the Inhibitory Effect of Adipose Tissue-Derived Stromal Cells on Prostate Cancer.

Takahara K, Ii M, Inamoto T, Nakagawa T, Ibuki N, Yoshikawa Y, Tsujino T, Uchimoto T, Saito K, Takai T, Tanda N, Minami K, Uehara H, Komura K, Hirano H, Nomi H, Kiyama S, Asahi M, Azuma H.

Stem Cells Dev. 2016 Sep 1;25(17):1290-8. doi: 10.1089/scd.2016.0093. Epub 2016 Aug 18.

PMID:
27465939
41.

[Overview of the ongoing clinical trials for new treatments for castrate-resistant prostate cancer (CRPC)].

Inamoto T, Azuma H.

Nihon Rinsho. 2016 May 20;74 Suppl 3:653-9. Japanese. No abstract available.

PMID:
27344811
43.

Prostatic Bleeding after Prostatic Biopsy Effects Oncological Outcomes with Laparoscopic Radical Prostatectomy.

Takai T, Inamoto T, Komura K, Tsujino T, Matsunaga T, Yoshikawa Y, Uchimoto T, Saito K, Tanda N, Minami K, Uehara H, Ibuki N, Takahara K, Nomi H, Kiyama S, Azuma H.

Asian Pac J Cancer Prev. 2016;17(3):1373-7.

44.

[A CASE OF ADVANCED BLADDER NEUROENDOCRINE CARCINOMA (SMALL CELL CARCINOMA) SIGNIFICANTLY IMPROVED BY LOW DOSE OF ORAL TEGAFUR-URACIL].

Nomi H, Takahara K, Minami K, Maenosono R, Matsunaga T, Yoshikawa Y, Tsujino T, Hirano H, Inamoto T, Yamamoto I, Tsuji M, Kiyama S, Azuma H.

Nihon Hinyokika Gakkai Zasshi. 2015 Oct;106(4):269-73. Japanese.

PMID:
26717786
45.

[Idiopathic Lumbar Hernia: A Case Report].

Tsujino T, Inamoto T, Matsunaga T, Uchimoto T, Saito K, Takai T, Minami K, Takahara K, Nomi H, Azuma H.

Hinyokika Kiyo. 2015 Nov;61(11):449-53. Japanese.

46.

The Anti-Proliferative Effect of Boron Neutron Capture Therapy in a Prostate Cancer Xenograft Model.

Takahara K, Inamoto T, Minami K, Yoshikawa Y, Takai T, Ibuki N, Hirano H, Nomi H, Kawabata S, Kiyama S, Miyatake S, Kuroiwa T, Suzuki M, Kirihata M, Azuma H.

PLoS One. 2015 Sep 1;10(9):e0136981. doi: 10.1371/journal.pone.0136981. eCollection 2015.

47.

E74-like factor inhibition induces reacquisition of hormone sensitiveness decreasing period circadian protein homolog 1 expression in prostate cancer cells.

Koyama K, Takahara K, Inamoto T, Ibuki N, Minami K, Uehara H, Komura K, Nishida T, Sakamoto T, Hirano H, Nomi H, Kiyama S, Azuma H.

Prostate Int. 2015 Mar;3(1):16-21. doi: 10.1016/j.prnil.2015.02.004. Epub 2015 Mar 10.

48.

Editorial Comment to Urethra-sparing high-intensity focused ultrasound for localized prostate cancer: Functional and oncological outcomes.

Inamoto T, Azuma H.

Int J Urol. 2015 Nov;22(11):1050. doi: 10.1111/iju.12894. Epub 2015 Aug 6. No abstract available.

49.

Positive voided urine cytology predicts worse pathological findings of nephroureterectomy specimens in patients with upper tract urothelial carcinoma: does selective ureteral cytology have an additional efficacy?

Sakano S, Inamoto T, Inoue R, Matsumoto H, Nagao K, Yamamoto Y, Azuma H, Matsuyama H.

Jpn J Clin Oncol. 2015 Oct;45(10):968-72. doi: 10.1093/jjco/hyv114. Epub 2015 Jul 30.

PMID:
26232447
50.

Role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma and the prognostic significance of C-reactive protein: A multi-institutional, retrospective study.

Fujita K, Inamoto T, Yamamoto Y, Tanigawa G, Nakayama M, Mori N, Tsujihata M, Azuma H, Nonomura N, Uemura M.

Int J Urol. 2015 Nov;22(11):1006-12. doi: 10.1111/iju.12868. Epub 2015 Jul 7.

Supplemental Content

Loading ...
Support Center